Use of bevacizumab in recurrent glioblastoma.

Published

Journal Article (Review)

Glioblastoma (GBM) is the most common adult primary brain neoplasm. Despite advances in treatment, GBM continues to be associated with considerable morbidity and mortality as compared with other malignancies. Standard treatment for GBM results in survival of 12.9 months (95% CI: 12.3-13.7 months) with a median progression-free survival of 7.2 months (95% CI: 6.4-8.2 months) in a modern GBM cohort. These aggressive tumors recur and treatment for recurrent GBM continues to have very poor outcomes. Prior to the use of bevacizumab, monoclonal antibody to VEGF, 6-month progression-free survival in clinical trials for recurrent GBM ranged from 9 to 15%. Trials utilizing bevacizumab and its subsequent US FDA approval have given more hope to recurrent GBM and this concise review discusses bevacizumab in recurrent GBM. This review focuses on time-to-event outcomes (overall survival, progression-free survival and 6-month progression-free survival) in clinical trials utilizing bevacizumab for the treatment of recurrent GBM. For this review, we have chosen to focus primarily on Phase II clinical trials that have been published and available in the literature (PubMed). While we focused primarily on time-to-event variables, toxicity and safety of bevacizumab is very important and this agent can be associated with serious life-threatening toxicities. We have included a general section of toxicities but for a more lengthy review please see the excellent study by Odia and colleagues.

Full Text

Duke Authors

Cited Authors

  • Ghiaseddin, A; Peters, KB

Published Date

  • 2015

Published In

Volume / Issue

  • 4 / 3

Start / End Page

  • 157 - 169

PubMed ID

  • 25906439

Pubmed Central ID

  • 25906439

Electronic International Standard Serial Number (EISSN)

  • 2045-0915

Digital Object Identifier (DOI)

  • 10.2217/cns.15.8

Language

  • eng

Conference Location

  • England